Analysts See $-1.24 EPS for Opiant Pharmaceuticals, Inc. (OPNT)

February 20, 2018 - By Max Morgan

 Analysts See $ 1.24 EPS for Opiant Pharmaceuticals, Inc. (OPNT)

Analysts expect Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) to report $-1.24 EPS on March, 15.They anticipate $6.15 EPS change or 125.25 % from last quarter’s $4.91 EPS. After having $-2.77 EPS previously, Opiant Pharmaceuticals, Inc.’s analysts see -55.23 % EPS growth. The stock decreased 4.19% or $1.11 during the last trading session, reaching $25.39. About 23,078 shares traded. Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) has 0.00% since February 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company has market cap of $52.50 million. The firm offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It has a 37.01 P/E ratio. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine.

More notable recent Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) news were published by: which released: “Opiant Pharmaceuticals, Inc. Announces NARCAN® Nasal Spray Royalty Monetization” on December 15, 2016, also with their article: “Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and …” published on February 08, 2018, published: “Opiant Pharmaceuticals, Inc. Announces Phase I Data for OPNT002 in Development …” on July 19, 2017. More interesting news about Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) were released by: and their article: “Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene …” published on February 12, 2018 as well as‘s news article titled: “Opiant Pharmaceuticals, Inc. Reports Fiscal First Quarter 2018 Financial Results” with publication date: December 04, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.